Rural areas may be more affected by adverse social and environmental factors than urban areas, Mitchell Elkind says.

TCTMD spoke with Lior Jankelson, MD, PhD (NYU Langone Health, New York, NY), an electrophysiologist who leads the AI/machine ...

The implication, some say, is that when TAVI expanded to lower-risk patients in 2019, death rates rose—not so fast, say others.

By slicing and dicing the data, the study confirms MITRA-FR as an outlier and emphasizes the need for careful patient selection.

NEW ORLEANS, LA—Adding the factor XIa inhibitor asundexian (Bayer) to antiplatelet therapy tops antiplatelet therapy alone ...

Citing lack of robust trial data, the committee offers algorithms and advice on care considerations in premenopausal ...

Much of the onus for creating change should fall to the device and pharmaceutical companies themselves, one expert says.

With the study adding to a mix of conflicting trial results, it’s not yet time to update guidelines, Shyam Prabhakaran says.

Those with preserved EF seemed to get more protection against HF events/CV death than those with reduced or unknown EF.

A bundle of protocols including patient education, skin prep, and glove changes reduced infections at a large US surgical ...

The mechanism remains unclear, but GLP-1 users had less MACE, CV death, and all-cause death driven by fewer amputations.